Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Vomiting 5Nausea 5Neoplasms 2Breast Neoplasms 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Aprepitant × Clear all
NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed
494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

NCT00212602 2012-06-14

ONO-7436 Phase II Study in Japan

Ono Pharmaceutical Co., Ltd.

Phase 2 Completed
420 enrolled

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡